Birchview Capital LP Acquires 20,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Birchview Capital LP lifted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 66.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company’s stock after buying an additional 20,000 shares during the period. 10x Genomics makes up 0.6% of Birchview Capital LP’s portfolio, making the stock its 26th biggest position. Birchview Capital LP’s holdings in 10x Genomics were worth $718,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Signaturefd LLC boosted its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after buying an additional 1,452 shares during the last quarter. Blue Trust Inc. grew its stake in shares of 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares during the period. Sound Income Strategies LLC grew its stake in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of 10x Genomics during the 4th quarter valued at about $52,000. Finally, SRS Capital Advisors Inc. lifted its stake in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is currently owned by institutional investors.

Insider Transactions at 10x Genomics

In other news, Director Alan Mateo acquired 40,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares of the company’s stock, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

10x Genomics Trading Down 0.1 %

Shares of TXG stock opened at $8.30 on Friday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.46 and a beta of 2.01. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $29.37. The stock’s 50-day moving average price is $9.47 and its 200-day moving average price is $13.11.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the subject of a number of research reports. Citigroup reduced their target price on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and a consensus price target of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.